Adjuvant Capital — Seed & Pre-Seed VC Firm ($250K–$2.5M Checks)
Adjuvant Capital is a Seed, Pre-Seed venture capital firm based in New York, NY investing in Healthcare. The firm typically writes $250K–$2.5M checks and has 20 portfolio companies in our records.
- Check size
- $250K–$2.5M
- Portfolio
- 20 companies on record
- Partners
- 5 listed
- AUM
- $300M
- Stage
- Seed, Pre-Seed
- Sectors
- Healthcare
- HQ
- New York, NY
Last verified: 2026-05-21
Seed, Pre-Seed
$250K – $2.5M
$300M
20+ companies
5 partners
About Adjuvant Capital
Adjuvant Capital is a venture capital firm headquartered in New York, NY. The firm invests in innovative technologies and therapies addressing major global health challenges, including oncology and genetic therapies.
Adjuvant Capital focuses on the healthcare, vaccines, and oncology sectors. It typically participates in seed, pre-seed, and early-stage financings with check sizes ranging from $250K to $2.5M. The firm has $300M in assets under management and prefers to be approached via warm introduction.
Investment Thesis
Invests in innovative technologies and therapies for major global health challenges, including oncology and genetic therapies.
How Adjuvant Capital invests
Adjuvant Capital is a vc firm based in New York, NY. The firm invests at the Seed, Pre-Seed stages, with a focus on Healthcare.
Adjuvant Capital typically writes checks of $250K–$2.5M per investment, backed by approximately $300M in assets under management.
Investing since at least 2019, Adjuvant Capital has backed 20 companies in our records, including LimmaTech Biologics, Curevo Vaccine, Memo Therapeutics.
Partners & Team
Industry Focus
Invests In
Recent Activity
Adjuvant Capital announces $300m venture fund to improve public health
Oct 2026 · Africa Global Funds
Adjuvant Capital Announces $300 Million Venture Fund Designed to Improve Global Public Health
Oct 2026 · Strategic Investment Fund / Gates Foundation
Operating Principles for Impact Management 2026 Disclosure Statement
Oct 2026 · Adjuvant Capital
Adjuvant Capital Publicly Shares its 2025 Annual Report
Oct 2026 · Adjuvant Capital
Adjuvant Capital Included in ImpactAssets 50 List for 2026
Mar 2026 · Adjuvant Capital
Investment Track Record
Adjuvant Capital has recorded investments in 21 companies. Its earliest recorded investment was made in 2019 and its most recent in 2023.
The firm's portfolio includes LimmaTech Biologics (2023, vaccine), Curevo Vaccine (2022, vaccine), Memo Therapeutics (2022, therapeutic), Antiva Biosciences (2021, therapeutic), Excision BioTherapeutics (2021, therapeutic), Pulmocide (2021, inhaled therapeutic), 54gene (2020, platform), ChromaCode (2020, platform), Codagenix (2020, platform), Evofem (2020, contraceptive), Frontier Nutrition (2020, lipid-based nutritional supplements), LakeShore Biopharma (2020, vaccine), MinervaX (2020, vaccine), Univercells (2020, process innovation), and VitriVax (2020, vaccine).
Portfolio Companies (20)
2023
LimmaTech Biologics
Vaccine development company working to halt AMR and STI infections.
2022
Curevo Vaccine
Next-generation subunit vaccines, initially targeting varicella and shingles.
Memo Therapeutics
Antibody discovery platform, initially targeting Nipah virus, SARS-CoV-2, CMV and BKV.
2021
Antiva Biosciences
Novel non-surgical therapeutic candidate to treat pre-cancerous cervical lesions caused by HPV.
Pulmocide
Novel therapies for patients suffering from serious acute and chronic respiratory diseases.
Excision BioTherapeutics
CRISPR-based therapies for chronic viral infectious diseases such as HIV and hepatitis B.
2020
LakeShore Biopharma
LakeShore is scaling up undersupplied global health vaccines and developing new biologics.
ChromaCode
ChromaCode's HD-PCR technology enhances multiplexing capabilities on existing hardware.
Codagenix
Codagenix uses emerging computational and synthetic biology tools to rationally design vaccines.
54gene
54gene is using African genetic data to drive discoveries in drug and vaccine development.
- •Raising at Seed, Pre-Seed? You're squarely in their sweet spot.
- •Lead with your fit in Healthcare — the sectors they actively back.
- •Size your ask to their typical $250K – $2.5M check.
- •warm intro preferred
- •Address your outreach to a specific partner, such as Kabeer Aziz, Partner.
- •A warm introduction beats a cold email. Get matched and request an intro.
Featured In
Browse More Investors
Fundraising resources
Frequently Asked Questions
See if Adjuvant Capital is a match for your startup
Upload your pitch deck to see how well you match with Adjuvant Capital and 10,000+ other investors.
Ask your AI assistant about this investor: connect InvestorMatch to Claude or ChatGPT
Is this your profile? Request a correction or removal